Citations

Showing 10 of 107930 citations.

Therapy of Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia in Adults: New Paradigms
Litzow, Mark R.

Mayo Clinic

Future Oncology | September 30, 2009 | Volume: 5 | Issue: 7 | Pages: 1039-1050

10.2217/fon.09.74 | PMID 19792972 Get It

Haplotype and Cell Proliferation Analyses of Candidate Lung Cancer Susceptibility Genes on Chromosome 15q24-25.1
Liu, Pengyuan , Wen, Weidong, James, Michael A. , Wang, Yian , Bailey‐Wilson, Joan E. , Pinney, Susan M. , Yang, Ping , Petersen, Gloria M. , Wiest, Jonathan S., Fain, Pamela R., Schwartz, Ann G. , Gazdar, Adi F. , Gaba, Colette , Rothschild, Henry, Mandal, Diptasri , Kupert, Elena, Lee, Juwon , Seminara, Daniela, Anderson, Marshall W., Liu, Yan , Amos, Christopher I. , Andrade, Mariza de , Minna, John Dorrance , You, Ming , Wilson, Richard K , Pinney, Susan M

Mayo Clinic

Cancer Research | September 29, 2009 | Volume: 69 | Issue: 19 | Pages: 7844-7850

10.1158/0008-5472.can-09-1833 | PMID 19789337 Get It

Abstract Recent genome-wide association studies have linked the chromosome 15q24-25.1 locus to nicotine addiction and lung cancer susceptibility. To refine the 15q24-25.1 locus, we performed a haplotype-based association analysis of 194 familial lung cases and 219 cancer-free controls from the Genetic Epidemiology of Lung Cancer Consortium (GELCC) collection, and used proliferation and apoptosis analyses to determine which gene(s) in the 15q24-25.1 locus mediates effects on lung cancer cell growth in vitro. We identified two distinct subregions, hapL (P = 3.20 × 10−6) and hapN (P = 1.51 × 10−6), which were significantly associated with familial lung cancer. hapL encompasses IREB2, LOC123688, and PSMA4, and hapN encompasses the three nicotinic acetylcholine receptor subunit genes CHRNA5, CHRNA3, and CHRNB4. Examination of the genes around hapL revealed that PSMA4 plays a role in promoting cancer cell proliferation. PSMA4 mRNA levels were increased in lung tumors compared with normal lung tissues. Down-regulation of PSMA4 expression decreased proteasome activity and induced apoptosis. Proteasome dysfunction leads to many diseases including cancer, and drugs that inhibit proteasome activity show promise as a form of cancer treatment. Genes around hapN were also investigated, but did not show any direct effect on lung cancer cell proliferation. We concluded that PSMA4 is a strong candidate mediator of lung cancer cell growth, and may directly affect lung cancer susceptibility through its modulation of cell proliferation and apoptosis. [Cancer Res 2009;69(19):7844–50]
Induction of Prostatic Intraepithelial Neoplasia and Modulation of Androgen Receptor by ETS Variant 1/ETS-Related Protein 81
Shin, Sook , Deursen, Jan M. van , Dehm, Scott M. , Tindall, Donald J., Grande, Joseph P. , Munz, Jan-Marie, Vasmatzis, George , Kim, Tae‐Dong , Jin, Fang , Janknecht, Ralf , Dehm, Scott M

Mayo Clinic

Cancer Research | September 29, 2009 | Volume: 69 | Issue: 20 | Pages: 8102-8110

10.1158/0008-5472.can-09-0941 | PMID 19789348 Get It

Abstract ETS variant 1 (ETV1), also known as ETS-related protein 81, is overexpressed in prostate tumors, but whether and how this transcription factor affects tumorigenesis has remained elusive. Here, we show that ETV1 is primarily overexpressed in the most aggressive human prostate tumors. Transgenic ETV1 mice developed prostatic intraepithelial neoplasia as well as hyperplasia/neoplasia in seminal vesicles. Moreover, ETV1 cooperated with the androgen receptor (AR) to bind to the prostate-specific antigen enhancer and stimulate gene transcription. Consistent with its ability to physically interact with AR, ETV1 rendered an ETV1 binding site–driven reporter androgen inducible, and, on the other hand, ETV1 superinduced transcription from an AR binding site on androgen stimulation. In conclusion, our study substantiates that ETV1 overexpression is an underlying cause in the development of prostate and possibly also seminal vesicle cancer. Its interaction with and activation of AR provides a molecular mechanism on how ETV1 exerts its deleterious function. Thus, inhibiting ETV1 or blocking its interaction with AR may represent novel strategies in prostate cancer therapy. [Cancer Res 2009;69(20):8102–10]
Expression of Insulin Receptor Isoform A and Insulin-like Growth Factor-1 Receptor in Human Acute Myelogenous Leukemia: Effect of the Dual-Receptor Inhibitor BMS-536924 In vitro
Hendrickson, Andrea E. Wahner , Haluska, Paul , Schneider, Paula A., Loegering, David A., Peterson, Kevin L., Attar, Ricardo M. , Erlichman, Charles , Gottardis, Marco M. , Karp, Judith E. , Carboni, Joan M., Peterson, Kevin L., Smith, B. Douglas , Kaufmann, Scott H.

Mayo Clinic

Cancer Research | September 29, 2009 | Volume: 69 | Issue: 19 | Pages: 7635-7643

10.1158/0008-5472.can-09-0511 | PMID 19789352 Get It

Abstract The insulin receptor (IR) and insulin-like growth factor-1 receptor (IGF1R) are receptor tyrosine kinases that participate in mitogenic and antiapoptotic signaling in normal and neoplastic epithelia. In the present study, immunoblotting and reverse transcription-PCR demonstrated expression of IGF1R and IR isoform A in acute myelogenous leukemia (AML) cell lines as well as in >80% of clinical AML isolates. Treatment with insulin enhanced signaling through the Akt and MEK1/2 pathways as well as survival of serum-starved AML cell lines. Conversely, treatment with BMS-536924, a dual IGF1R/IR kinase inhibitor that is undergoing preclinical testing, inhibited constitutive receptor phosphorylation as well as downstream signaling through MEK1/2 and Akt. These changes inhibited proliferation and, in some AML cell lines, induced apoptosis at submicromolar concentrations. Likewise, BMS-536924 inhibited leukemic colony formation in CD34+ clinical AML samples in vitro. Collectively, these results not only indicate that expression of IGF1R and IR isoform A is common in AML but also show that interruption of signaling from these receptors inhibits proliferation in clinical AML isolates. Accordingly, further investigation of IGF1R/IR axis as a potential therapeutic target in AML appears warranted. [Cancer Res 2009;69(19):7635–43]
Infection and Killing of Multiple Myeloma by Adenoviruses
Senac, Julien S., Doronin, Konstantin, Russell, Stephen J. , Jelinek, Diane F., Greipp, Philip R., Barry, Michael A. , Russell, Stephen J , Barry, Michael A

Mayo Clinic

Human Gene Therapy | September 29, 2009 | Volume: 21 | Issue: 2 | Pages: 179-190

10.1089/hum.2009.082 | PMID 19788385 Get It

Oncolytic virotherapy makes use of the natural ability of viruses to infect and kill cancer cells. Adenovirus serotype 5 (Ad5) has been approved for use in humans as a therapy for solid cancers. In this study, we have tested whether Ad5 and low-seroprevalence adenoviruses can be used as oncolytics for multiple myeloma (MM). We show that Ad5 productively infects most myeloma cell lines, replicates to various degrees, and mediates oncolytic cell killing in vitro and in vivo. Comparison of Ad5 with low-seroprevalence Ads on primary marrow samples from MM patients revealed striking differences in the abilities of different adenoviral serotypes to kill normal CD138 – cells and CD138 + MM cells. Ad5 and Ad6 from species C and Ad26 and Ad48 from species D all mediated killing of CD138 + cells with low-level killing of CD138 – cells. In contrast, Ad11, Ad35, Ad40, and Ad41 mediated weak oncolytic effects in all of the cells. Comparison of cell binding, cell entry, and replication revealed that Ad11 and Ad35 bound MM cells 10 to 100 times better than other serotypes. However, after this efficient interaction, Ad11 and Ad35 viral DNA was not replicated and cell killing did not occur. In contrast, Ad5, Ad6, Ad26, and Ad48 all replicated 10- to 100-fold in MM cells and this correlated with cell killing. These data suggest that Ad5 and other low-seroprevalence adenoviruses may have utility as oncolytic agents against MM and other hematologic malignancies.
Hypertension during Pregnancy is Associated with Coronary Artery Calcium Independent of Renal Function
Cassidy‐Bushrow, Andrea E. , Bielak, Lawrence F. , Sheedy, Patrick F. , Garovic, Vesna D. , Peyser, Patricia A. , Rule, Andrew D. , Turner, Stephen T. , Garovic, Vesna D

Mayo Clinic

Journal of Women's Health | September 28, 2009 | Volume: 18 | Issue: 10 | Pages: 1709-1716

10.1089/jwh.2008.1285 | PMID 19785565 Get It

Background: Hypertension during pregnancy (HDP) increases the risk of future coronary heart disease (CHD), but it is unknown whether this association is mediated by renal injury. Reduced renal function is both a complication of HDP and a risk factor for CHD. Methods: Logistic regression models were fit to examine the association between a history of HDP and the presence and extent of coronary artery calcification (CAC), a measure of subclinical coronary artery atherosclerosis, in 498 women from the Epidemiology of Coronary Artery Calcification Study (mean age 63.3 ± 9.3 years). Results: Fifty-two (10.4%) women reported a history of HDP. After adjusting for age at time of study participation, HDP was associated with increased serum creatinine later in life ( p = 0.014). HDP was positively associated with the presence of CAC after adjusting for age at time of study participation (OR = 2.7, 95% CI 1.4-5.4). This association was slightly attenuated with adjustment for body size and blood pressure (OR = 2.4, 95% CI 1.2-4.9) but was not further attenuated with adjustment for serum creatinine and urinary albumin/creatinine ratio (OR = 2.6, 95% CI 1.3-5.3). Results were similar for CAC extent. Conclusions: HDP may increase a woman's risk of future CHD beyond traditional risk factors and renal function. Women with a history of HDP should be monitored for potential increased risk of CHD as they age.
Atrophy patterns in IVS10+16, IVS10+3, N279K, S305N, P301L, and V337M MAPT mutations
Whitwell, Jennifer L. , Jack, Clifford R. , Senjem, Matthew L. , Baker, Matt , Ivnik, Robert J., Petersen, R. C., Rademakers, Rosa , Josephs, Keith A. , Boeve, Bradley F. , Knopman, David S. , Wszołek, Zbigniew K. , Jack, Clifford R , Senjem, Matthew L

Mayo Clinic

Neurology | September 28, 2009 | Volume: 73 | Issue: 13 | Pages: 1058-1065

10.1212/wnl.0b013e3181b9c8b9 | PMID 19786698 Get It

Characterization of PCEng2, a β-1,3-Endoglucanase Homolog in Pneumocystis carinii with Activity in Cell Wall Regulation
Villegas, Leah R., Kottom, Theodore J. , Limper, Andrew H.

Mayo Clinic

American Journal of Respiratory Cell and Molecular Biology | September 25, 2009 | Volume: 43 | Issue: 2 | Pages: 192-200

10.1165/rcmb.2009-0131oc | PMID 19783787 Get It

Abstract Pneumocystis jirovecii pneumonia is an opportunistic fungal infection that causes severe respiratory impairment in immunocompromised patients. The viability of Pneumocystis organisms is dependent on the cyst cell wall, a structural feature that is regulated by essential cell wall–associated enzymes. The formation of the glucan-rich cystic wall has been previously characterized, but glucan degradation in the organism—specifically, degradation during trophic excystment—is not yet fully understood. Most studies of basic Pneumocystis biology have been conducted in Pneumocystis carinii or Pneumocystis murina, the varieties of this genus that infect rats and mice, respectively. Furthermore, all known treatments for P. jirovecii were initially discovered through studies of P. carinii. Accordingly, in this study, we have identified a P. carinii β-1,3-endoglucanase gene (PCEng2) that is demonstrated to play a significant role in cell wall regulation. The cDNA sequence contained a 2.2-kb open reading frame with conserved amino acid domains homologous to similar fungal glycosyl hydrolases (GH family 81). The gene transcript showed up-regulation in cystic isolates, and the expressed protein was detected within both cyst and trophic forms. Complementation assays in Eng2-deleted Saccharomyces cerevisiae strains showed restoration of the cell wall separation defect during proliferation, demonstrating the importance of PCEng2 protein. during fungal growth. These findings suggest that regulation of cyst cell wall β-glucans is a fundamental process during completion of the Pneumocystis life cycle.
Asthma and sarcoplasmic reticulum Ca2+ reuptake in airway smooth muscle
Prakash, Y. S. , Sathish, Venkatachalem , Sieck, Gary C. , Thompson, Michael A. , Pabelick, Christina M. , Prakash, Y S , Sieck, Gary , Sathish, Venkatachalem

Mayo Clinic

American Journal of Physiology-Lung Cellular and Molecular Physiology | September 25, 2009 | Volume: 297 | Issue: 4 | Pages: L794-L794

10.1152/ajplung.00237.2009 | PMID 19783641 Get It

Sex/Gender Medicine The Biological Basis for Personalized Care in Cardiovascular Medicine
Arain, Faisal A., Kuniyoshi, Fatima H. Sert , Abdalrhim, Ahmed D., Miller, Virginia M. , Sert Kuniyoshi, Fatima H

Mayo Clinic

Circulation Journal | September 25, 2009 | Volume: 73 | Issue: 10 | Pages: 1774-1782

10.1253/circj.cj-09-0588 | PMID 19729858 Get It